Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VRTX |
---|---|---|
09:32 ET | 8914 | 460.7 |
09:34 ET | 2251 | 460 |
09:36 ET | 1645 | 460.94 |
09:39 ET | 733 | 460.57 |
09:41 ET | 1065 | 460 |
09:43 ET | 4098 | 460 |
09:45 ET | 3276 | 459.505 |
09:48 ET | 2530 | 459.21 |
09:50 ET | 900 | 460.3 |
09:52 ET | 1112 | 460.205 |
09:54 ET | 2804 | 460.09 |
09:57 ET | 710 | 460.5 |
09:59 ET | 1507 | 460.89 |
10:01 ET | 2791 | 461.41 |
10:03 ET | 1000 | 461.13 |
10:06 ET | 250 | 461.26 |
10:08 ET | 2640 | 460.35 |
10:10 ET | 300 | 460.785 |
10:12 ET | 2059 | 461.435 |
10:14 ET | 300 | 461.8 |
10:15 ET | 5132 | 461.72 |
10:17 ET | 500 | 461.71 |
10:19 ET | 300 | 461.85 |
10:21 ET | 2734 | 461 |
10:24 ET | 2347 | 460.25 |
10:26 ET | 4328 | 460 |
10:28 ET | 100 | 459.975 |
10:30 ET | 2029 | 460 |
10:32 ET | 894 | 459.54 |
10:33 ET | 6928 | 458.965 |
10:35 ET | 2867 | 459.03 |
10:37 ET | 719 | 459.375 |
10:39 ET | 3700 | 459.38 |
10:42 ET | 1497 | 458.5 |
10:44 ET | 2792 | 457 |
10:46 ET | 2398 | 457.55 |
10:48 ET | 200 | 457.1201 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Vertex Pharmaceuticals Inc | 119.3B | -225.8x | +46.35% |
Regeneron Pharmaceuticals Inc | 114.7B | 27.2x | +10.93% |
Biogen Inc | 27.5B | 23.3x | -18.14% |
ICON PLC | 24.4B | 34.3x | +4.68% |
IQVIA Holdings Inc | 42.2B | 29.7x | +46.62% |
Moderna Inc | 24.3B | -4.0x | --- |
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $119.3B |
---|---|
Revenue (TTM) | $10.3B |
Shares Outstanding | 258.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.40 |
EPS | $-2.02 |
Book Value | $68.22 |
P/E Ratio | -225.8x |
Price/Sales (TTM) | 11.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3.37% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.